
SCGP's 2024 Performance

Total revenue from sales was recorded at Baht 132,784 million, an increase of 3% year-on-year, primarily driven by growth in domestic demand, which led to an increase in sales volumes of packaging paper, fiber packaging, consumer and performance packaging, and foodservice packaging. Additionally, the export market improved especially in consumer-related segments. Furthermore, lower inflation played a significant role in enhancing demand for durable goods.

EBITDA was reported at Baht 16,127 million, a 9% year-on-year decrease, with an EBITDA margin of 12%. Profit for the year amounted to Baht 3,699 million, a 30% year-on-year decrease, and net profit margin was 3%. The decline in EBITDA and profit was mainly due to the lower performance of packaging paper operations, which were affected by increased recovered paper costs, along with significant foreign currency fluctuations in ASEAN, particularly in the third quarter of 2024. Furthermore, the profit for the year included the impact from additional stake in Indonesia operation since September 2024. Despite the reduction in margins, efforts were made to enhance production utilization, operational excellence, and cost management across the value chain.







Major Events and Business Updates

SCGP continues to pursue growth through merger and partnership (M&P), which enlarges its customer base and enables the creation of value-accretive synergy across operations. The expedition of organic expansions to increase production capacity has also led to enhance packaging solutions capabilities to serve growing customer demand.

In 2024, SCGP successfully executed 1 merger and partnership (M&P) project and 1 organic expansion in Thailand. Meanwhile, SCGP made an investment and received approval from the Board of Directors for a capital increase in Indonesia. The company also engaged in joint development with strategic partners to expand its presence in ASEAN and enhance medical supplies and labware solutions in Thailand. Specific details are as follows:

1. Merger and Partnership (M&P)

Thailand (Consumer and performance packaging, Rayong) - SCGP has acquired a 90% stake in VEM (Thailand) Company Limited (VEM-TH) with an investment of approximately Baht 146 million. This acquisition is a part of SCGP's strategy to expand its healthcare packaging and supplies business and meet the increasing demand. VEM-TH operates 30 plastic injection mold production lines that comply with ISO 13485 (The global standard for medical device quality management system) and has certified cleanrooms of class 8 and class 7, producing over 59 million pieces of premium quality products annually. VEM-TH currently serves clients in the medical, aircraft, electrical parts, and automotive industries, with a market coverage including Thailand, US, China, and



other countries. This acquisition enhances and adds production capabilities of Deltalab S.L. and Bicappa Lab S.r.L. This transaction also allows SCGP to expand its international customer network more robustly and effectively. VEM-TH's financial performance has been consolidated since July 2024.

2. Organic Expansion

Thailand (Fiber packaging, Samutsakorn and Samutprakan) - Organic expansion of corrugated carton operation to serve Thailand's growing demand with maximized asset utilization and elevate production efficiency with the latest available technology. The project adds 75,000 tons per year of production capacity, which equals 9% of total capacity in Thailand. This project is strategically located at the center of customers' production hub, making it a pivotal factor in accommodating growing customer demand especially in food & beverage and other consumer-linked segment along with improving logistics cost competitiveness. This project started commercialization in March 2024.

3. Investment and capital increase

Indonesia (Packaging paper, Jakarta) - The completion of an additional 44.48% share acquisition in PT Fajar Surya Wisesa Tbk. (Fajar) on 30 August 2024 through SCGP Solutions (Singapore) Pte. Ltd. (SCGPSS), a wholly owned subsidiariy of SCGP, with total transaction amount of USD 652.42 million or equivalent to Baht 22,802 million. After the transaction, SCGP's stake in Fajar has increased to 99.71%, from 55.23% previously. Meanwhile, the remaining 0.29% shares are held by the public.

In addition, the Board of Directors has approved Fajar's proposal to increase its capital by granting Preemptive Rights to the Company's shareholders through a limited public offering mechanism, with a maximum of 1 billion new ordinary shares. The company intends to use all proceeds received to reduce its liabilities and increase working capital. The Extraordinary General Meeting of Shareholders of Fajar was conducted on 22 January 2025.

4. Memorandum of Understanding (MOU)

Memorandum of Understanding (MOU) between SCGP and Once Medical Co., Ltd. - The collaboration, signed on 1 October 2024, specifically focuses on the development of syringes, medical supplies, and labware. The primary objective of this partnership is to fortify SCGP's packaging solutions and medical supplies business, while also expanding the customer network.

